- Poster presentation
- Open Access
The kinetics of HTLV-1 proviral load after allogeneic hematopoietic cell transplantation with reduced intensity conditioning regimen; a comparison with that from sibling donors and that from unrelated donors
© Choi et al; licensee BioMed Central Ltd. 2014
- Published: 7 January 2014
- Elderly Patient
- Virus Type
- Conditioning Regimen
- Undetectable Level
- Unrelated Donor
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy that is caused by human T-lymphotropic virus type 1 (HTLV-1) with poor prognosis. We have reported the feasibility and efficacy of allogeneic hematopoietic cell transplantation with reduced intensity conditioning (RIC-HCT) for elderly patients with ATL, and have also shown that in more than half of patients the HTLV-1 proviral load (HTLV-PL) decreased to an undetectable level after RIC-SCT, suggested presence of anti HTLV-1 effects. In this study, we try to compare the kinetics of HTLV-PL after RIC-SCT from HTLV-1 antibody negative sibling donor (SD) with that from unrelated donors (UD), all of whom were HTLV-1 antibody negative. Fourteen patients were included in the SD group, and fifteen patients were in UD group. The HTLV-PL decreased to an undetectable revel in 11 of 14 patients (78.6%) in the SD group and 13 of 15 (86.7%) in the UD group with in 120 days after RIC-SCT. In short term, the kinetics of the HTLV-PL after RIC-SCT from UD was almost similar to that from HTLV-1 negative SD. Looking at the long term follow-up results, the HTLV-PL remains to be an undetectable level in only 2 of 11 (18.2%) patients in the SD group (median follow up 111 months [101-122])), on the other hand, 7 of 13 (53.8%) patient in the UD group (24 month [20-36]). RIC-HCT from UD tends to have better anti-HTLV-1 effect, compared with that from SD, but not conclusive because of the short follow-up period.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.